After J.P. Morgan and H.C. Wainwright gave ChemoCentryx (NASDAQ: CCXI) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Harshita Polishetty reiterated a Buy rating on ChemoCentryx today and set a price target of $19.00. The company’s shares closed last Monday at $6.89, close to its 52-week low of $6.16.
According to TipRanks.com, Polishetty is a 3-star analyst with an average return of 6.2% and a 40.7% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ChemoCentryx with a $18.67 average price target, implying a 175.8% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $23.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.98 and a one-year low of $6.16. Currently, ChemoCentryx has an average volume of 394.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
